-
The global strategic market access consultancy with over 20 years thought leadership partnering with Pharma and Biotech Clients.
Helping healthcare companies enable patients gain rapid and maintained access to life saving and enhancing healthcare, through innovative Market Access solutions globally.
Services Domains
-
Value Strategy
Defining the Value Strategy for your brand is the most important decision you will make, as it will affect the lives of patients, and the overall contribution of the brand to the company.
-
Value Evidence Identification
GalbraithWight are experts in identifying the clinical, HEOR and RWE evidence required by Payers to ensure you can deliver on the Value Strategy for your brand.
-
Value Evidence Generation
The quality of the evidence generated to support the value assessment of new medicines is coming under greater scrutiny by Payer organizations around the world.
-
Value Communication
Communicating the Value of our Clients’ brands is where all the evidence and planning comes together.
-
Value Confirmation
Many believe that Market Access is all about national pricing and reimbursement approval. The truth is that now, Payers will continue to explore the value being delivered by your brand well after launch.
Introduction to GalbraithWight from Colin Wight, CEO
Latest News More News
-
NewsGalbraithWight celebrates 21 years of global strategic Market Access expertise
2018 represents GalbraithWight’s 21st Anniversary – so a very big thank you to our fantastic team and our wonderful clients who have made our past 21 years as the leading global strategic market access consultancy such a success!
-
ArticleIntroducing Bio-Map Europe: the strategic market access plan ‘in a box’ for Biotech
If you are an innovative, SME Biotech company, in the clinic, with a potential approval in the next 3-4 years, but concerned about the evidence you will need to achieve successful pricing and reimbursement in the highly complex European markets, Bio-MAP Europe was designed specifically for you.
-
VideoGalbraithWight CEO, Colin Wight talks about our new service Bio-MAP Europe: the strategic market access plan ‘in a box’ for Biotech
Are you a SME Biotech who is in the clinic, with funding, a European launch to plan for in the next 3-4 years and concerned about how to navigate complex pricing and reimbursement approval across the many European countries? I am proud to announce the launch of a new service specifically designed for you; Bio-MAP Europe.
